14037 results for "Buy fc coins Buyfc26coins.com is EA Sports official for FC 26 coins Their customer service is very responsive..7ZgM"

in 89.73 milliseconds.

• Thymic epithelial transplantation for complete DiGeorge syndrome Spatial (2025-07-28)

  Spatial transcriptomics study of thymic transplant biopsies . This dataset contains all the data available for this study on 2025-07-28.

  Dataset EGAD00001015659

• WGS files for paper titled "Patient-derived pediatric brain tumor organoids faithfully recapitulate primary tumors"

  WGS files for paper titled "Patient-derived pediatric brain tumor organoids faithfully recapitulate primary tumors"

  Dataset EGAD00001015800

• RNASeq files for paper titled "Patient-derived pediatric brain tumor organoids faithfully recapitulate primary tumors"

  RNASeq files for paper titled "Patient-derived pediatric brain tumor organoids faithfully recapitulate primary tumors"

  Dataset EGAD00001015802

• Remaining WGS files for Klco RPAML data

  Remaining WGS files for study titled "Genomics of pediatric myeloid neoplasms"

  Dataset EGAD00001008446

• Single cell whole genome sequencing of 5 ovarian cancer specimens

  Single cell whole genome sequencing BAM files for five ovarian cancer specimens.

  Study EGAS50000001458

• Two lung cancer cell lines with EGFR mutations, PC-9 and KHM-3S, were either treated with Tarceva for 24 hours or left untreated. The gene expression profiles were examined by RNAseq, and the genome wide binding profiles of total STAT3 and pSTAT3 were characterized by ChIPseq.

  Lung cancers harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as Tarceva. However, nearly all patients show relapse within 1 year after initial treatment. To investigate the early signaling switches that are involved in the formation of drug resistance, and the role of STAT3 in the early signaling switches involved in the formation of drug resistance, we have treated two lung cancer cell lines with EGFR mutations, PC-9 and KMH-3S, with Tarceva for 24hours. The RNA samples with and without treatment were collected in triplicate for RNAseq experiment.The total STAT3 and pSTAT3 chromatinIP were done on samples with and without treatment for ChIPseq.

  Study EGAS00001000793

• A benchmarking resource for NGS testing of cancer predisposition genes

  A benchmarking resource of 639 individuals, to assess the analytical sensitivity of cancer predisposition gene (CPG) testing.The dataset includes sequencing data generated using the TruSight Cancer Panel (TSCP) a targeted NGS assay for analysis of CPGs and orthogonally generated data supporting at least one pathogenic variant in a CPG for a total of 645 pathogenic CPG variants.The set of pathogenic CPG variants includes strong representation of some of the most challenging types of pathogenic variants, with 339 indels, including 16 complex indels and 24 insertions or deletions with length greater than 5bp, and 74 exon CNVs, including 23 single exon CNVs. There are 502 pathogenic variants in BRCA1 or BRCA2, making this an important first-line validation dataset for laboratories performing NGS testing of BRCA1 and BRCA2.

  Study EGAS00001002993

• Molecular Analysis of Short- Versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma

  The underlying determinants for long-term survival (LTS, ≥10 years) versus short-term survival (STS, <3 years) of patients diagnosed with high-grade serous ovarian carcinoma (HGSC) are largely unknown. The present study sought to identify molecular predictors of LTS for women with HGSC. A cohort of 24 frozen HGSC samples (12 LTS and 12 STS) were collected and analyzed at DNA and RNA levels. Copy number variation and mutation did not indicate large differences between LTS and STS. From RNA-Seq analysis, 11 genes were found to be differentially expressed between the STS and LTS groups (fold change >2; false discovery rate <0.01). In the validation cohort, transmembrane protein 62 (TMEM62) was found to be related to LTS. Our in vitro and in vivo studies demonstrate that restoring TMEM62 may be a novel approach for treatment of HGSC. These findings may have implications for biomarker and intervention strategies to help improve patient outcomes.

  Study phs003020

• NIDCD Otitis Media Genetic Susceptibility and Middle Ear Microbial Shifts

  The study funded by R01 DC015004 aims to: (1) Identify rare OM susceptibility variants within families and in probands; and (2) Identify differences in the middle ear microbiome due to OM susceptibility variants. This study will also elucidate mechanisms responsible for the formation and growth of cholesteatoma, and bony erosion and complications due to cholesteatoma e.g. intracranial, hearing/vestibular loss, facial nerve palsy. A better understanding of cholesteatoma pathogenesis will potentially reveal novel drug targets, which can lead to new non-surgical therapies for cholesteatomatous OM. Our specific aims for this administrative supplement are: Aim 1 -- Perform RNA-sequencing using cholesteatoma samples collected from Filipino and Colorado patients who will be screened for FUT2, SPINK5 and A2ML1 variants; and Aim 2 -- Using network analysis, identify bone-expressed proteins potentially interacting with FUT2, SPINK5 or A2ML1, then test protein expression in archival human temporal bone in direct contact with cholesteatoma.

  Study phs001941

• Characterizing Individual Cells Obtained from Bone Marrow Biopsies of MPN Patients

  We profiled the transcriptomes of individual cells obtained from bone marrow aspirates of 7 treatment-naïve newly diagnosed JAK2-mutant myeloproliferative neoplasm (MPN) patients (3 polycythemia vera and 4 essential thrombocythemia patients), and 2 healthy controls. The submitted data corresponds to sequencing reads mapped to the human reference genome GhRC38 build using CellRanger for a total of 9 samples (one per patient). In addition, to reconstruct the lineage histories of single cells in MPN patients, we performed whole-genome sequencing of single-cell-derived colonies of hematopoietic stem and progenitor cells from 2 essential thrombocythemia (ET) patients: 22 JAK2-mutant colonies and 20 WT colonies for patient ET 1; and 13 JAK2-mutant colonies and 21 WT colonies for patient ET 2. The submitted data consists of sequencing reads aligned to the human reference genome GhRC38 build using bwa-mem. Each file corresponds to the whole-genome sequencing data for one colony.

  Study phs002308

• Spatial Transcriptomics Reveals Discrete Tumor Microenvironments and Autocrine Loops Within Ovarian Cancer Subclones

  Ovarian masses from patients with high grade serous ovarian carcinoma undergoing debulking surgery were subjected to spatial transcriptomics profiling using the 10x Genomics Visium (fresh frozen) platform. Copy number inference using inferCNV predicted the presence of subclones with mutually exclusive copy number alterations (CNAs) in 5 of the 8 patient samples studied. In one patient, 3 subclones were predicted. For this patient sample, a serial section of the same tumor was used to microdissect regions corresponding to each of these subclones, and a 'normal' region predicted to contain only fibroblasts and no tumor cells. These microdissected regions were processed for low pass whole genome sequencing (WGS) and CNAs recorded using ichorCNA. An oral biopsy lacking tumor cells from an unrelated donor was used as a negative control for CNA inference. The CNAs predicted by inferCNV for the three subclones were validated by the low pass WGS and no CNAs were observed in the normal region containing fibroblasts.

  Study phs003561

• GRIDSS, PURPLE, LINX: Unscrambling the tumor genome via integrated analysis of structural variation and copy number

  We have developed a novel, integrated and comprehensive purity, ploidy, structural variant and copy number somatic analysis toolkit for whole genome sequencing data of paired tumor/normal samples. We show that the combination of using GRIDSS for somatic structural variant calling and PURPLE for somatic copy number alteration calling allows highly sensitive, precise and consistent copy number and structural variant determination, as well as providing novel insights for short structural variants and regions of complex local topology. LINX, an interpretation tool, leverages the integrated structural variant and copy number calling to cluster individual structural variants into higher order events and chains them together to predict local derivative chromosome structure. LINX classifies and extensively annotates genomic rearrangements including simple and reciprocal breaks, LINE, viral and pseudogene insertions, and complex events such as chromothripsis. LINX also comprehensively calls genic fusions including chained fusions. Finally, our toolkit provides novel visualisation methods providing insight into complex genomic rearrangements.

  Study EGAS00001004034

• Serial TERT rearrangement breakpoint quantification in circulating tumor DNA enables minimal residual disease monitoring in patients with neuroblastoma

  Approximately 30% of high-risk neuroblastomas harbor genomic TERT rearrangements at diagnosis, resulting in high TERT transcript levels and active telomerase. Combined with mutations in the RAS/MAPK/ALK signaling transduction network, these patients have a dismal prognosis. Our objective was to establish a liquid biopsy-based monitoring strategy for this particularly vulnerable patient subgroup, for whom no in-time molecular diagnostic tools exist to date. Detection and quantification of TERT rearrangement breakpoints in cell-free tumor DNA circulating in peripheral blood and bone marrow plasma from patients with TERT-driven neuroblastoma improved minimal residual disease monitoring and early relapse detection in individual patients. TERT rearrangement breakpoints, as a single marker or combined with mutations in the RAS/MAPK/ALK signaling transduction network, can be reliably analyzed from 1ng DNA using droplet digital PCR assays fit for clinical routine use. TERT rearrangement breakpoints are reflected in cell-free tumor DNA and can serve as robust biomarkers for disease activity.

  Study EGAS00001007365

• Sequencing data from MethylScan assay on plasma

  Machine learning models in biomedical research are often hindered by demographic imbalances in clinical datasets, leading to biased predictions that disadvantage minority populations. Existing bias correction methods face limitations in handling the heterogeneity of biomedical data and the complexity of demographic influences. Here, we present DeBias, a computational framework for mitigating demographic biases in high-dimensional biomedical datasets. DeBias eliminates bias-associated subspaces within the entire feature space using control samples and enables global bias correction across all features, effectively preserving disease-specific signals while minimizing demographic distortions. To demonstrate its effectiveness, we applied DeBias to cfDNA methylation data for cancer detection. It achieved a >6-fold reduction in the number of features containing biases and outperformed existing methods in improving the cancer detection performance for minority populations. Our method represented a promising step toward developing machine learning models that are more accurate, reliable, and equitable for minority populations.

  Study EGAS00001008127

• HCC.GNE RNA-Seq

  RNA-Sequencing data (raw read sequences) for 23 samples, from 12 patients, for the study "Diverse modes of genomic alterations in Hepatocellular Carcinoma"

  Dataset EGAD00001000886

• CCA methylation data (12 CCA, 7 normal)

  Raw idat files for DNA methylation profiling for 12 CCAs and 7 normal bile duct tissues. DNA methylation profiling was performed using Infinium MethylationEPIC v2.0 Kit.

  Dataset EGAD00010002613

• RNA-seq data for Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood BALL

  RNA-seq data for 14 samples with B-cell acute lymphoblastic leukemia

  Dataset EGAD50000000151

• Single-cell RNA-seq of Bone marrow samples

  For two donors, we collected CD34 plus and CD34 minus hematopoietic cells for the single-cell RNA-seq analysis.

  Dataset EGAD50000000514

• WGS data for genomic determinants of response and resistance to inotuzumab in B-ALL

  Whole genome sequencing data for 45 samples with B-cell acute lymphoblastic leukemia

  Dataset EGAD50000000096

• WES data for genomic determinants of response and resistance to inotuzumab in B-ALL

  Whole exome sequencing data for 69 samples with B-cell acute lymphoblastic leukemia

  Dataset EGAD50000000097

• Whole exome sequencing of prDLBCL

  To investigate the mutational landscape of prDLBCL, 34 cases were selected for whole exome sequencing.

  Study EGAS50000000403

• sc-DECISION

  Data derived from PBMC and blood samples for the single cell and bulk RNAseq analysis for the sc-DECISION paper. https://doi.org/10.1101/2025.02.04.25321370

  Dataset EGAD50000001622

• HeLa S3 (CCL-2.2) HiC Sequencing

  HiC chromatin conformation sequencing was performed for the purpose of chromosome fusion and structural rearrangement identification.

  Study phs000665

• Liver Regulatory Genomics Data Access Committee

  Data access committee for genomic datasets generated for human liver tissue and human primary liver cells by the Regulatory Genomics of Metabolic Disease group (Imperial College London, Section of Genetics and Genomics).

  Dac EGAC50000000715

• single cell transcriptomic analysis of tumor samples collected from 5 patients with EMM

  Contains the raw single cell RNAseq data used for the study

  Study EGAS50000000034

• Normal sample for patient SA224

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA224

  Dataset EGAD00001009548

• Tumour sample for patient SA720

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA720

  Dataset EGAD00001009585

• Exome and Transcriptome for gynecologic cancer gene-drug analysis

  Total of 180 gynecologic tumor specimens were subjected for targeted-exome and/or whole-transcriptome sequencing.

  Dataset EGAD00001005331

• Tumour sample for patient SA588

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA588

  Dataset EGAD00001009194

• Tumour sample for patient SA601

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA601

  Dataset EGAD00001009205

• Tumour sample for patient SA590

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA590

  Dataset EGAD00001009196

• Tumour sample for patient SA654

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA654

  Dataset EGAD00001009206

• Normal sample for patient SA604

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA604

  Dataset EGAD00001009217

• Normal sample for patient SA398

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA398

  Dataset EGAD00001009231

• Normal sample for patient SA221

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA221

  Dataset EGAD00001009362

• Tumour sample for patient SA425

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA425

  Dataset EGAD00001009356

• Tumour sample for patient SA234

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA234

  Dataset EGAD00001009525

• Tumour sample for patient SA226

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA226

  Dataset EGAD00001009532

• Tumour sample for patient SA231

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA231

  Dataset EGAD00001009535

• Normal sample for patient SA591

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA591

  Dataset EGAD00001009241

• Exome and Transcriptome for gastric cancer gene-drug analysis

  Newly generated 52 gastric tumor specimens were subjected for targeted-exome and/or whole-transcriptome sequencing

  Dataset EGAD00001005766

• Tumour sample for patient SA591

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA591

  Dataset EGAD00001009197

• TENX066

  Transcriptome profiling by high-throughput sequencing for single cells for library TENX066 1 samples; filetype=fastq

  Dataset EGAD00001006481

• SCRNA10X_SA_CHIP0149_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0149_001 1 samples; filetype=fastq

  Dataset EGAD00001006467

• SCRNA10X_SA_CHIP0080_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0080_001 1 samples; filetype=fastq

  Dataset EGAD00001006461

• SCRNA10X_SA_CHIP0142_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0142_001 1 samples; filetype=fastq

  Dataset EGAD00001006464

• SCRNA10X_SA_CHIP0142_003

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0142_003 1 samples; filetype=fastq

  Dataset EGAD00001006465

• SCRNA10X_SA_CHIP0146_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0146_002 1 samples; filetype=fastq

  Dataset EGAD00001006466

• SCRNA10X_SA_CHIP0149_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0149_002 1 samples; filetype=fastq

  Dataset EGAD00001006468

• SCRNA10X_SA_CHIP0150_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0150_002 1 samples; filetype=fastq

  Dataset EGAD00001006470

• SCRNA10X_SA_CHIP0152_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0152_001 1 samples; filetype=fastq

  Dataset EGAD00001006471

• SCRNA10X_SA_CHIP0163_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0163_002 1 samples; filetype=fastq

  Dataset EGAD00001006474

• TENX064

  Transcriptome profiling by high-throughput sequencing for single cells for library TENX064 1 samples; filetype=fastq

  Dataset EGAD00001006479

• RNA data for Glioblastoma (EGAS00001003953, H016)

  RNA data for human glioblastoma patients, EGAS00001003953. 64 human samples, 2 cell lines (LN229, ZH487).

  Dataset EGAD00001006547

• SCRNA10X_SA_CHIP0080_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0080_002 1 samples; filetype=fastq

  Dataset EGAD00001006462

• SCRNA10X_SA_CHIP0163_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0163_001 1 samples; filetype=fastq

  Dataset EGAD00001006473

• SCRNA10X_SA_CHIP0063_000

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0063_000 1 samples; filetype=fastq

  Dataset EGAD00001006478

• SCRNA10X_SA_CHIP0152_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0152_002 1 samples; filetype=fastq

  Dataset EGAD00001006472

• SCRNA10X_SA_CHIP0172_001

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0172_001 1 samples; filetype=fastq

  Dataset EGAD00001006475

• TENX062

  Transcriptome profiling by high-throughput sequencing for single cells for library TENX062 1 samples; filetype=fastq

  Dataset EGAD00001006477

• TENX065

  Transcriptome profiling by high-throughput sequencing for single cells for library TENX065 1 samples; filetype=fastq

  Dataset EGAD00001006480

• Tumour sample for patient SA676

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA676

  Dataset EGAD00001009343

• Tumour sample for patient SA1028

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1028

  Dataset EGAD00001009614

• Tumour sample for patient SA600

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA600

  Dataset EGAD00001009204

• SCRNA10X_SA_CHIP0172_002

  Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0172_002 1 samples; filetype=fastq

  Dataset EGAD00001006476

• Normal sample for patient SA495

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA495

  Dataset EGAD00001009372

• Tumour sample for patient SA668

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA668

  Dataset EGAD00001009211

• DATA FILES FOR MULLIGHAN MEF2D RNASEQ STRANDED

  DATA FILES FOR MULLIGHAN MEF2D RNASEQ STRANDED

  Dataset EGAD00001002692

• Normal sample for patient SA1026

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA1026

  Dataset EGAD00001009587

• Tumour sample for patient SA101

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA101

  Dataset EGAD00001009527

• Tumour sample for patient SA277

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA277

  Dataset EGAD00001009539

• Normal sample for patient SA237

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA237

  Dataset EGAD00001009558

• Normal sample for patient SA576

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA576

  Dataset EGAD00001009596

• Normal sample for patient SA530

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA530

  Dataset EGAD00001009234

• Tumour sample for patient SA276

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA276

  Dataset EGAD00001009182

• Tumour sample for patient SA655

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA655

  Dataset EGAD00001009207

• Normal sample for patient SA402

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA402

  Dataset EGAD00001009232

• Tumour sample for patient SA592

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA592

  Dataset EGAD00001009198

• Tumour sample for patient SA595

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA595

  Dataset EGAD00001009200

• Tumour sample for patient SA599

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA599

  Dataset EGAD00001009203

• Tumour sample for patient SA283

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA283

  Dataset EGAD00001009184

• Normal sample for patient SA665

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA665

  Dataset EGAD00001009252

• Normal sample for patient SA404

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA404

  Dataset EGAD00001009233

• Normal sample for patient SA535

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA535

  Dataset EGAD00001009235

• Tumour sample for patient SA279

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA279

  Dataset EGAD00001009183

• Tumour sample for patient SA398

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA398

  Dataset EGAD00001009188

• Tumour sample for patient SA593

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA593

  Dataset EGAD00001009199

• Normal sample for patient SA605

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009218

• Normal sample for patient SA609

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009219

• Normal sample for patient SA595

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA595

  Dataset EGAD00001009244

• Normal sample for patient SA599

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA599

  Dataset EGAD00001009247

• Normal sample for patient SA655

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA655

  Dataset EGAD00001009251

• Normal sample for patient SA671

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA671

  Dataset EGAD00001009256

• Tumour sample for patient SA609

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009262

• Tumour sample for patient SA994

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA994

  Dataset EGAD00001009259

• Tumour sample for patient SA605

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009261

• Normal sample for patient SA669

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA669

  Dataset EGAD00001009255

• Tumour sample for patient SA674

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA674

  Dataset EGAD00001009341

• Tumour sample for patient SA673

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA673

  Dataset EGAD00001009340

• Tumour sample for patient SA675

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA675

  Dataset EGAD00001009342